Entrectinib in NTRK fusion-positive non-small cell lung cancer

Bookmark and Share
Published: 18 Apr 2019
Views: 1125
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain

Dr Luis Paz-Ares speaks to ecancer at the European Lung Cancer Congress 2019 about an integrated analysis of the STARTRK-2, STARTRK-1 and ALKA-372-001 trials.

Dr Paz-Ares outlines the mechanism of entrectinib in a genetically specific set of patients, and also the benefits specifically to those with CNS metastases.

He finalises by explaining the toxicity profile, but also that this drug should be given to more patients over a wider range of cancer types to provide more data.